PharmaTalkRadio

DPharm podcast series # 2

 MIT Professor, Dina Katabi, PhD gave one of the best talks on in home non-intrusive patient monitoring at DPharm 2017 and provided a demo of technology that uses ambient radio signals to monitor a patient’s gait, falls, breathing, heart rate and even sleep, all without putting any sensor on the patient’s body. Find out how they have used the technology to redefine clinical endpoints and pushed clinical trials to the home. The next DPharm conference is September 25-26 in Boston. DPharm reports on innovation and disruptive innovation to advance clinical trials and supports the community behind the movement. 

Speaker: Dina Katabi, PhD

MacArthur Fellow, Andrew & Erna Viterbi Professor, MIT, and Director of MIT Center for Wireless Networks and Mobile Computing

Producer: Valerie Bowling, Executive Director, DPharm

The Conference Forum presents a 1 day meeting on Immuno-Oncology Clinical Trial Operations, February 8th at the Roosevelt hotel in NYC. It’s part of the IO360 conference, which runs over three days from Feb 7th through the 9th.  The OPERATIONS portion of this conference is offered as a stand alone program.  This podcast gives a brief summary of what to expect.

The morning provides first hand reporting on new trends and emerging technologies. The afternoon goes through 7 components including: the patient perspective, site management, 3rd parties, clinical supply chain, a PI perspective, data management and project management. 

Many thanks to Andy Lee, SVP, Head of Global Clinical Trial Operations at Merck for his guidance on the topic and for bringing his team to help us understand the building blocks, providing a really unique insight into obtaining the necessary precision IO trial operations require. 

For information, go to www.theconferenceforum.org

The 2nd annual Patients as Partners EU is the only conference in Europe that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. In this short podcast, Valerie Bowling, executive director at the Conference Forum gives a brief summary of what to expect at this conference and runs through the highlights. 

Chairs:

Tony Hoos, MD, PhD, MBA

Head of Medical, Amgen Europe

Andrew Garvey

Global Patient Advocacy Lead, GlaxoSmithKline

The premier event was attended by roughly 150 people and the program brings back:

Accreditation by Patients Included “Ask the Patient” program to give attendees the opportunity to meet a group of individuals who’ve experienced a clinical trial.Attendee “Tool-Box” and an assortment of specially designed materials to help capture ideas.

Patients as Partners EU is co-produced with industry, patient advocacy and government to establish a well-rounded program that addresses the needs of all stakeholders seeking to implement and advance patient involvement across the entire clinical development continuum with the goal of driving greater efficienices. It is attended primarily by pharmaceutical operation and advocacy executives and patient advocacy trusts.  There is a small exhibit room with tons of networking. 

January 23-24, 2018 Radisson Blu Portman Hotel, London, UK

For more information visit www.theconferenceforum.org 

Special rates for trusts and use code TEML for 10% off.

If you are interested in hearing the 2017 drug delivery landscape year in review in 2017, please email [email protected]

Chair of the Partnership Opportunities in Drug Delivery (PODD) event, Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche, presents an annual year-in-review of the drug delivery landscape from 2016. Dr Lueckel’s opening remarks are a highlight of PODD every year, and we’re excited to have her return as program chair for the 2018 event, coming up on October 17-18 in Boston. We will post Dr Lueckel's 2017 overview of the drug delivery market shortly. 

About Dr Lueckel:

Since end of 2014, Barbara leads the Research & Technologies Partnering (RTP) team belonging to the Innovation Partnering group in Roche Partnering. RTP team members lead evaluations & negotiations with biotech companies in an effort to enhance the discovery efforts of Roche’s Research & Early Development organization (pRED) across all of its therapeutic areas – either applying technology platforms to targets or molecules of interest to pRED (including drug delivery), or collaborating on early stage molecules. RTP team members are also responsible for alliance management of the resulting license agreements. Barbara joined Roche in 2007 as a Global Drug Delivery Evaluator, and transitioned to the Research & Technologies Partnering team in 2012. She is trained as a pharmacist with a PhD from the University of Basel.

Pan American Games Champion, Olympian and World Championship silver medalist, Jennifer Goldsack, became a world-class athlete while working and studying at the University of Oxford. How did she do it? She recently shared her story with DPharm Director, Valerie Bowling, discussing the lessons she learned from her Olympic experience and how she uses them in her professional life at the Clinical Trials Transformation Initiative (CTTI).

Ms Goldsack manages the development and implementation of Clinical Trials Transformation Initiative (CTTI) projects. In collaboration with team leaders, she creates project plans and budgets, and manages the implementation of those plans. She earned her master’s degree in chemistry from the University of Oxford, England, her masters in the history and sociology of medicine from the University of Pennsylvania, and her MBA from the George Washington University. Additionally, she is a certified Lean Six Sigma Green Belt and a Certified Professional in Healthcare Quality. 

Ms Goldsack spent five years working in research at the Hospital of the University of Pennsylvania, first in Outcomes Research in the Department of Surgery and later in the Department of Medicine. More recently, Ms Goldsack helped launch the Value Institute, a pragmatic research and innovation center embedded in a large academic medical center in Delaware. 

Ms Goldsack recently presented at the Mobile in Clinical Trials conference organized by the Conference Forum. For more information, visit: www.theconferenceforum.org.

Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO including:

Discovery / Preclinical ScienceTranslational ScienceClinical DevelopmentBusiness AspectsInvestor RelationsEmerging TechnologiesBiomarkers / DiagnosticsTrends in the Field

Dr Axel Hoos, GSK and Dr James Gulley, NCI, together led the design of the 4th annual Immuno-Oncology 360° program to include 45 speakers and over 30 talks. Save the date: February 7-9, 2018 in New York City.

The Conference Forum is pleased to share a podcast featuring keynote speaker and world renowned customer service expert, Dr Chip Bell who spoke at the 6th annual DPharm: Disruptive Innovations to Advance Clinical Trials on the topic of service in clinical trials.

To truly service our patients, we need to understand service together with science. Can service be a disrupter in clinical research? In this keynote, Dr Bell tells us how to think like a service industry, why it’s worth it for R&D and how to get started. Dr Bell gives the listener practical insights on how to give patients a great experience. Although this podcast is primarily focused on serving patients in clinical research, you will find that hospitals and physician offices/medical groups will also benefit.

The 8th annual DPharm conference will continue to cover service, but through a patient perspective. DPharm 2018 takes place September 25-26 in Boston. For more information, www.theconferenceforum.org

About Dr Chip Bell:

Dr Bell is considered a world-renowned authority on customer loyalty and service innovation. He has authored eight national best-selling books. For more information visit, www.chipbell.com

Originally recorded during the 4th annual Patients as Partners US event held in Philadelphia, March 2017, Bristol-Myers Squibb’s Mary Stober-Murray moderates this multi-stakeholder panel to discuss what patients truly want when it comes to clinical care and patient involvement. Patients John Creveling, a Parkinson’s Foundation Research Advocate, and Deb Maskens from the International Kidney Cancer Coalition, join her and representing the industry perspective are Paul Graves from Takeda Pharmaceuticals and Dr Michelle Vichnin from Merck.

Closing the gap between clinical care and patients wants/needs:

• Ask patients what’s going on in their lives.

• Ask patients what their goals are.

• Because no one asks patients these questions, the result is they get care that’s aligned with what the doctor thinks is clinically relevant, even though it may be completely out of context to what is important to the patient.

What patients want and how pharma can help:

• Identify what patients and industry want respectively in terms of patient involvement and why that is meaningful for each.

• What can we do to enhance this across the development pipeline?

• What is getting in the way? Identify hurdles.

• How can we work through this collaboratively?

Initially developed out of the first DPharm event, the Patients as Partners US program seeks to understand and incorporate the patient's voice in designing clinical trials and developing a clinical endpoint, as well as vastly improve the patient's entire experience in a clinical trial. The 5th annual Patients as Partners US will be March 15-16, 2018, in Philadelphia.

Internationally recognized digital health expert, Donald Jones, MBA, Chief Digital Officer at Scripps Translational Science Institute, shares his insights on the digital clinical trial landscape and the urgent need to pair digitization with drug products for patients during his keynote address from the 2016 CMO Summit.

The Chief Medical Officer Summit is designed for CMOs and R&D Leadership from small to mid-size life science companies. The 6th Annual CMO Summit will be held May 7-8, 2018, in Boston.

In this multi-stakeholder session from the 4th annual Patients as Partners US meeting, patients, advocates, industry and nonprofit organizations come together to discuss how they partnered and the outcomes of those partnerships.

• What’s the roadmap?

• What are the ways you have partnered with industry?

• What are some best practices or rules of engagement?

• How can the pharma industry better serve patient advocacy organizations?

• How are we creating and ruthlessly maintaining transparency and trust?

• Addressing global models of patient engagement

• Big companies are working in global environment and the Patient Engagement issues are quite different culturally, whether it’s China, Japan, Asia. What are the unique challenges and opportunities in countries outside US and EU?

Moderated by Lori Abrams, Director, Diversity and Patient Engagement, Bristol-Myers Squibb, panelists included: Stephanie Christopher, Program Manager, Patient Centered Benefit-Risk, Medical Device Innovation Consortium; Lauren McLaughlin, Associate Director, Research Partnerships, The Michael J Fox Foundation for Parkinson’s Research; Suzanne Schrandt, JD, Director, Patient Engagement, Arthritis Foundation; Nirmala Singh Steering Committee, Patient Focused Medicines Development and Former Patient Engagement Director, National Kidney Foundation.

The 5th annual Patients as Partners US will be held March 15-16, 2018 at The Rittenhouse, Philadelphia, PA, USA.